120
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Combination of bendamustine-azacitidine against Syk target of breast cancer: an in silico study

, , , , , & show all
Pages 13950-13962 | Received 14 Nov 2022, Accepted 28 Jan 2023, Published online: 26 Apr 2023
 

Abstract

Breast cancer (BC) is the most serious and second leading cause of death in women worldwide. When breast cancer is diagnosed and treated early, the chance of long-term survival is up to 90%. On the other hand, 90% of BC patient deaths are due to metastasis and a lack of effective early diagnosis. The existing conventional chemotherapy provides negative feedback due to transportation barriers towards the action sites, multidrug resistance, poor bio-availability, non-specific delivery and systemic side effects on the healthy tissue. Syk protein Kinase has been reported in BC, as a tumor modulator, providing a pro-survival signal and also by restricting epithelial-mesenchymal transition, enhancing cell-cell interactions and inhibiting migration. In the present study, we explored the possibility of targeting BC by attenuating Syk protein Kinase. Hence, we have conjugated the hydrophobic Bendamustine (BEN) and hydrophilic Azacitidine (AZA) anticancer drugs to evaluate their efficacy against BC. The native drugs (BEN and AZA) and designed drug-drug conjugate (BEN-AZA) were docked with Syk protein. Then, the docked complex was performed for Binding Free Energy and Molecular Dynamics Simulations. Furthermore, DFT and ADME properties were carried out. The results revealed that the designed drug-drug conjugate has a better docking score, ΔGbind and admirable stability throughout the simulation when compared with native drugs. In DFT and ADME analyses, the designed drug-drug conjugate has shown good stereo electronic features and pharmaceutical relevant parameters than that of native drugs. The overall results suggested that the designed drug-drug conjugate may be a suitable candidate for BC treatment.

Communicated by Ramaswamy H. Sarma

Disclosure statement

The authors declare no competing interests.

Author’s contribution

Sankar Muthumanickam: investigation, methodology, writing – original draft, Balajee Ramachandran: conceptual idea, conceptualization, writing, and proof outline, Pandi Boomi: conceptualization, methodology, writing – review & editing, supervision, Jeyaraman Jeyakanthan: contributed to the final version of the manuscript, Halliah Gurumallesh Prabu: writing – review & editing, supervision, Sonamuthu Jegatheshwaran: concept and methodology discussion, Kumpati Premkumar: writing – review & editing, supervision.

Additional information

Funding

SM thanks the Indian Council of Medical Research (BMI/11(41)/2022 dated: 20.06.2022) for providing ICMR-SRF (Senior Research Fellowship). The authors thankfully acknowledge the UGC-Innovative [No. F.14-13/2013 (Inno/ASIST)], DST-FIST [SR/FST/LSI- 667/2016(C)], DST PURSE [SR/PURSE Phase 2/38 (G)], MHRD-RUSA 2.0 [F.24/51/2014-U, Policy (TNMulti-Gen), Department of Education Government of India] and DBT-BIC [BT/PR40154/BTIS/137/34/2021] for financial support and infrastructure facilities.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.